Triple-Negative Breast Cancer (TNBC) Not Yet Recruiting Phase 2 Trials for Sacituzumab govitecan (DB12893)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02161679Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerTreatment